Type 1 Diabetes

Justin M. Gregory, MD, MSC, reviews the risk factors of T1D, highlighting a family history of T1D and antibody screening.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Linda A. DiMeglio, MD, comments on the importance of early diagnosis of T1D, giving patients the advantage of preparing a treatment plan early.

Expert endocrinologists review the importance of staging and classifying T1D, highlighting dysglycemia.

The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.

However, the analysis suggests young adults with T2D who underwent vitrectomy for PDR had worse final visual acuity and more complications compared to those with T1D.

Justin M. Gregory, MD, MSC, and Linda A. DiMeglio, MD, provide an overview of the pathophysiology of type 1 diabetes.

Schafer Boeder, MD, discusses the incidence of type 1 diabetes, highlighting risk factors such as age and family history.

An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

Women with type 1 diabetes experience a three times greater risk of sexual dysfunction than women without diabetes.

Fear of hypoglycemia is associated with negative outcomes in people with T1D that may influence psychosocial well-being and diabetes management.

A microsimulation model leveraging data from NHANES suggests monthly prescriptions of fruits and vegetables to people with diabetes and food insecurity could prevent nearly 300,000 cardiovascular disease events over a 25-year period.

Administration of SGLT2 inhibitors may prove unfavorable for skeletal muscle mass in type 1 diabetes, according to a posthoc analysis of the RISING-STAR study.

After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.

Announced by Tandem Diabetes Care on July 11, 2023, the Tandem Mobi insulin pump is billed as the world's smallest insulin pump, at less than half the size of the t:slim X2 pump and able to fit in a coin pocket.

Analyses show BMI at T1D diagnosis and the rate of weight gain at 3 months post-diagnosis in female patients were associated with disordered eating behaviors.

Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.

Widespread use of continuous glucose monitoring was not found to attenuate the association between impaired awareness of hypoglycemia and diabetes-related distress.

Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.

An analysis from ADA 2023 suggests meeting or exceeding 7,000 - 10,000 steps per day is associated with marginal improvements in time in range in adults with T1D.

Our endocrinology month in review for June 2023, highlights FDA decisions in type 1 and type 2 diabetes, studies from ENDO 2023, and new data presented at the 83rd Scientific Sessions of the American Diabetes Association.

An analysis from ADA 2023 suggests adults with T1D and higher social determinants of health risks are less likely to perform behaviors to maintain health.

David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.

The AHEAD program was associated with promising reductions in mean diabetes distress scores among emerging adults with type 1 diabetes.

A combination of in-office and telehealth visits increased visit frequency and maintained glycemic control in older adults with T1D during the COVID-19 pandemic.